The implications of new cholesterol guidelines on a rural Midwest community

November 17, 2014

Minneapolis, MN - November 17, 2014 - At the 2014 American Heart Association Scientific Sessions in Chicago, Ill., Minneapolis Heart Institute Foundation Research Cardiologist Dr. Michael Miedema gave a presentation entitled "The Implications of the Recent American College of Cardiology/American Heart Association Guidelines for the Treatment of Blood Cholesterol on a Rural Community: The Heart of New Ulm Project."

"The recently released cholesterol guidelines appear to have significantly increased the number of middle-aged adults who qualify for a cholesterol-lowering statin," stated Miedema. "We wanted to evaluate what the impact of the guidelines will be on a rural community because these populations are rarely included in traditional research cohorts."

In the study, Dr. Miedema and his colleagues analyzed the electronic health data from 4,281 residents of New Ulm, Minn. The study subjects were between the ages of 40 and 79, with a mean age of 59.4 years, and 52.7 percent of the subjects were female. The data studied was from health care visits that occurred during 2012 - 2013, before the release of the new ACC/AHA cholesterol guidelines. The new guideline criteria were applied to the sample to determine the potential impact of implementation of the guidelines.

Dr. Miedema found that, under the new guidelines, 59 percent of the study subjects met one of the four major indications for statin therapy. But of that number, only 65 percent were on a statin at the time of the assessment. Additionally, only 11% were taking a high-intensity statin. The new guidelines recommend routine use of "high-intensity" statins. Full doses of atorvastatin and rosuvastatin are considered high-intensity statins.

The new guidelines especially increase qualification for statin therapy in older individuals, with researchers finding that 86% of individuals over age 60 qualified for statin therapy. "Our results confirm that, in a rural population, the new cholesterol guidelines substantially increase the number of individuals who qualify for a statin. The biggest driver of this increase is that a substantially larger number of older individuals without known heart disease qualify for a statin under the new guidelines, and that's a controversial area. We definitely need more research aimed at figuring out the best methods to determine who should and should not take a statin," concluded Miedema.

The annual American Heart Association Scientific Sessions is the leading cardiovascular conference for basic, translational, clinical and population science with more than 15,000 cardiovascular health experts in attendance. The 2014 sessions are being held at McCormick Place in Chicago, Ill.
-end-
About the Minneapolis Heart Institute Foundation

The Minneapolis Heart Institute Foundation is dedicated to creating a world without heart disease through groundbreaking clinical and population health research and community outreach. MHIF's mission is to improve people's lives through the highest quality cardiovascular research and education. Contact:
Teresa Ambroz
Minneapolis Heart Institute Foundation
612-863-9041
TAmbroz@mhif.org

Minneapolis Heart Institute Foundation

Related Cholesterol Articles from Brightsurf:

Cholesterol's effects on cellular membranes
The findings have far-reaching implications in the general understanding of disease, the design of drug delivery methods, and many other biological applications that require specific assumptions about the role of cholesterol in cell membranes.

Autism-cholesterol link
Study identifies genetic link between cholesterol alterations and autism.

Microbes might manage your cholesterol
Researchers discover a link between human blood cholesterol levels and a gene in the microbiome that could one day help people manage their cholesterol through diet, probiotics, or entirely new types of treatment.

Experimental cholesterol-lowering drug effective at lowering bad cholesterol, study shows
Twice-yearly injections of an experimental cholesterol-lowering drug, inclisiran, were effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol, in patients already taking the maximum dose of statin drugs, according to data of the ORION-10 trial presented Saturday, Nov.

Rethinking how cholesterol is integrated into cells
Cholesterol is best known in connection with cardiovascular disease, but cholesterol is also vital for many fundamental processes in the body.

Seed oils are best for LDL cholesterol
Using a statistical technique called network meta-analysis, researchers have combined the results of dozens of studies of dietary oils to identify those with the best effect on patients' LDL cholesterol and other blood lipids.

Cholesterol leash: Key tethering protein found to transport cellular cholesterol
Cholesterol is an essential component of living organisms, but the mechanisms that transport cholesterol inside the cell are poorly understood.

New way to treat cholesterol may be on the horizon
A breakthrough discovery by scientists at Houston Methodist Research Institute could change the way we treat cholesterol.

How low should LDL cholesterol go?
New analysis shows that in a high-risk population, achieving ultra-low LDL cholesterol levels, down to <10 mg/dL, safely results in additional lowering of risk of cardiovascular events.

Does boosting 'good' cholesterol really improve your health?
A new review addresses the mysteries behind 'good' HDL cholesterol and why boosting its levels does not necessarily provide protection from cardiovascular risk for patients.

Read More: Cholesterol News and Cholesterol Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.